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ABSTRACT
Objective To compare the incidence of tuberculosis over
two years in infants vaccinated at birth with intradermal
BCG or with percutaneous BCG.
Design Randomised trial.
Setting South Africa.
Participants 11680 newborn infants.
InterventionsInfantswererandomisedbyweekofbirthto
receiveTokyo172BCGvaccinethroughthepercutaneous
route (n=5775) or intradermal route (n=5905) within 24
hours of birth and followed up for two years.
Main outcome measures The primary outcome measure
wasdocumentedMycobacteriumtuberculosisinfectionor
radiologicalandclinicalevidenceoftuberculosisdisease.
Secondary outcome measures were rates of adverse
events, all cause and tuberculosis specific admissions to
hospital, and mortality.
Results The difference in the cumulative incidence of
definite,probable,andpossibletuberculosisbetweenthe
intradermal group and the percutaneous group, as
definedusingstudydefinitionsbasedonmicrobiological,
radiological, and clinical findings was −0.36% (95.5%
confidence interval −1.27% to 0.54%). No significant
differences were found between the routes in the
cumulative incidence of tuberculosis using a range of
equivalence of “within 25%.” Additionally, no significant
differences were found between the routes in the
cumulative incidence of adverse events (risk ratio 0.98,
95% confidence interval 0.91 to 1.06), including deaths
(1.19, 0.89 to 1.58).
Conclusion Equivalence was found between intradermal
BCG vaccine and percutaneous BCG in the incidence of
tuberculosis in South African infants vaccinated at birth
and followed up for two years. The World Health
Organization should consider revising its policy of
preferential intradermal vaccination to allow national
immunisation programmes to choose percutaneous
vaccination if that is more practical.
Trial registration ClinicalTrials.gov NCT00242047.
INTRODUCTION
AccordingtotheWorldHealthOrganization8.9million
newcasesoftuberculosisand1.7milliondeathsfromthe
diseaseoccurredin2004.Tuberculosiskillsordebilitates
more people aged between 15 and 59 than any other
disease and accounts for 26% of all preventable deaths.
More women of childbearing age in developing
countries die from tuberculosis than from any other
pregnancy or childbirth associated causes. The global
annualincidenceoftuberculosiscontinuestoincreasein
AfricabecauseoftheHIVepidemic,whereasinallother
regionsitisstableorfalling.Theeffectivenessoftheonly
licensed vaccine for tuberculosis, Bacille Calmette-
Guerin (BCG), is only partial.
12
BCG vaccine is given to nearly all newborn infants or
youngchildreninmostdevelopingcountries,becauseitis
thought to provide 80% protection against tuberculous
meningitis and miliary disease, but protection against
lung tuberculosis is highly variable.
34Since itsfirst usein
humans in 1921, BCG has been given by a variety of
routes,includingbymouth,byintradermalinjection,and
percutaneously using a multipuncture injection device.
Currently the intradermal route is most commonly
used. It is the only method recommended by WHO.
5
Compared with the percutaneous route the intra-
dermal route is said to deliver a more precise dose of
vaccine,
6is cheaper,
7 and mayalso induce higherrates
oftuberculinskintestconversion.Skintestconversion
is, however, a poor correlate of BCG induced
protection against tuberculosis. Variable application
techniquesand differingdevicesmayalter the number
of bacilli given and possibly change the response to
vaccination.
58-11 Early studies have claimed that
vaccinationbytheintradermalrouteinducesa“better”
immune response than by the percutaneous route.
Thesefindingsarequestionedbyourrecentreportson
higherfrequenciesofBCGspecificinterferon-γprodu-
cing T cells; greater secretion of interferon-γ, tumour
necrosis factor α, and interleukin 2; lower secretion of
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proliferationafterpercutaneousvaccinationcompared
with intradermal vaccination.
1213
SomecountriespreferpercutaneousBCGbecauseof
concerns about adverse events associated with the
intradermal route, including pain, inflammatory
changes,
14 and abscesses.
15 One such country was
Japan, which switched to using percutaneous BCG in
1966 as those responsible thought this route was less
reactogenic than the intradermal route.
16 As of 2000,
Japan and South Africa were the only two countries
withlargeBCGvaccinationprogrammesthatstillused
the percutaneous route.
In 1999, following a consultative meeting, the South
African National Department of Health decided to
changefromthepercutaneousroutetointradermalroute
to fall in line with WHO recommendations. Consensus
was,however,lackingastowhichmethodwasbetterfor
protection against clinical tuberculosis and complica-
tions of the disease. Therefore, along with a recommen-
dation to change vaccination policy the meeting
recommended that additional research on methods of
BCGvaccinationshouldbecarriedout.Wecarriedouta
randomised trial to compare the incidence of tubercu-
losis over two years in infants vaccinated at birth with
intradermal BCG or with percutaneous BCG.
METHODS
We carried out the study in a rural region of South
Africa, located 100 km north east of Cape Town. In
2001 the study area had a population of 310860, a
reported annual incidence of tuberculosis in adults of
515 per 100000, a reported HIV seroprevalence in
pregnant women attending public antenatal clinics
ranging from 5.7% to 6.2%, and an estimated rate of
tuberculosis in under 5s of 2.5% per annum.
1718
We included infants if they were born at one of the
five public obstetric units in the study area, were
eligible to receive routine BCG vaccination within the
first 24 hours of birth, and their mothers were resident
in the study area.
Interventions
The BCG Laboratory in Tokyo, Japan, provided
preparationsoftheTokyo172BCGsubstrainvaccine.
We chose this vaccine because it is the only commer-
cially available product that comes in both percuta-
neous and intradermal formulations. The vaccine was
givenaccordingtomanufacturer’sinstructionsandthe
dosage determined and justified by the manufacturer.
Intradermal BCG was given in a dose of 0.05 ml
(20×10
6 colony forming units/ml) from a single dose
plastic syringe through a short bevelled 10 mm
25 gauge intradermal needle, into the lower deltoid
region of the right arm at the insertion point of the
muscle.Forthepercutaneousvaccineweevenlyspread
onedropofsolution,containing80mg/mlBCG(3×10
9
colony forming units/ml), over the skin and, using a
nine pronged vaccination tool (BCG Laboratory),
perforated the skin three quarters of the way up the
right upper arm in the deltoid area, and a second time
about 2 cm more distally. The percutaneous product
needs to be given at a titre about 1.5 times higher than
the intradermal product to achieve similar results
(tuberculin skin test conversion). The infants were
vaccinated within 24 hours of birth.
Outcome measures
Ourprimaryoutcomewastheincidenceoftuberculous
eventsininfantsaftervaccinationwithTokyo172BCG
administered by either the percutaneous route or the
intradermal route. We considered events with bacter-
iological or histological confirmation or that met strict
clinical criteria, occurring in the two years after birth.
Our null hypothesis was that there would be a
difference in the incidence of tuberculosis between
the groups on the basis of a prespecified margin for
equivalence.
Our secondary outcomes were the rates of adverse
events, including local and systemic ones related to
vaccination, admissions to hospital for all causes and
for tuberculosis, and mortality. A further objective of
thistrialwastoshowthecapacitytodoavaccinetrialin
this environment according to the standards expected
oftheInternationalConferenceonHarmonisationand
WHO good clinical practice.
Quality of measurements
Ifwesuspectedtuberculosisinanyoftheinfantsbefore
age 2 years on the basis of a history of contact or
because they exhibited signs or symptoms of the
Microbiology
Tuberculosis culture positive or tuberculosis smear positive
and tuberculosis polymerase chain reaction positive
Radiology
Chest radiograph compatible with or suggestive of tuberculosis
Clinical
Diagnosed as having
tuberculosis by treating clinician
Clinical
>2 additional features*
of tuberculosis
excluding failure to
thrive or loss of weight
if infected with HIV
Clinical
>2 additional features*
of tuberculosis
excluding failure to
thrive or loss of weight
if infected with HIV
Clinical
>1 additional features* of tuberculosis
excluding failure to thrive or
loss of weight if infected with HIV
Definite
tuberculosis
Probable
tuberculosis
Possible
tuberculosis
Unlikely
tuberculosis
Not
tuberculosis
No Yes
No Yes
No Yes No
* Additional features: Tuberculosis smear positive or tuberculosis culture negative; tuberculosis smear negative or
   tuberculosis polymerase chain reaction positive; cough for >2 weeks’ duration; Mantoux test >15 mm or 5 mm if HIV
   infected or tine test grade 3 or 4; failure to thrive or recent weight loss; tuberculosis contact
Yes
No Yes No Yes
Fig 1 | Diagnostic algorithm for confirmation of tuberculosis in infants. Those who underwent
investigations on the ward were admitted directly from their homes and were relatively well.
Those requiring in-patient treatment for unrelated conditions were admitted for investigation of
tuberculosis after hospital discharge and resolution of coexistent illness
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verification of the disease. A study doctor and, when
appropriate, study nurses carried out a clinical
examination, chest radiography, tuberculin skin test-
ing, HIV testing, and both gastric aspiration and
sputum induction for mycobacterial culture. Con-
firmed tuberculosis was categorised as definite, prob-
able, or possible using a diagnostic algorithm (fig ).
Infants who tested positive for HIV were referred for
further evaluation and management to a specialist
hospital.
The algorithm classified suspected cases into defi-
nite, probable, possible, and unlikely. Definite tuber-
culosis required microbiological confirmation of M
tuberculosis; probable tuberculosis required a chest
radiograph suggestive of the disease (lymphadenopa-
thy, miliary pattern, pleural effusion, bronchial com-
pression, or parenchymal infiltrate) plus at least one
additionalfeatureoftuberculosis;possibletuberculosis
required either a chest radiograph suggestive of
tuberculosis in the absence of any additional feature
of the disease, or a chest radiograph not suggestive of
tuberculosis but a diagnosis of tuberculosis by the
treating clinician and the presence of at least two
additionalfeaturesofthe disease.Duringfollow-upwe
alsocollecteddataonlocalandsystemiceventsrelated
tovaccination,admissionstohospitalforallcausesand
for tuberculosis, and mortality.
Sample size, interim analyses, and stopping rules
The trial was designed to evaluate whether the two
routes of BCG administration were equivalent in
preventing tuberculosis. The null hypothesis was that
t h e r ew o u l db ead i f f e r e n c ei nt h ei n c i d e n c eo f
tuberculosis between the two groups of at least Δ,
where Δ equalled 25%. A range of equivalence of
within25%wasprespecifiedbasedoninterpretationof
a clinically meaningful difference associated with the
different routes. We estimated the rate of tuberculosis
at 2.5%per annumin thispopulation.Thebirth ratein
the study area was estimated to be 6302 per annum.
17
The percentageof the birth cohort expected to receive
BCG was estimated to exceed 85%, based on BCG
coverage rates collected routinely by the regional
health department.
18 As the intervention was a single
administrationofthevaccineweanticipatedtherateof
withdrawal to be zero. The infant mortality rate was
expected to be about 35 per 1000
19 live births and the
mortality rate in the second year to be 9 per 1000 live
births per annum.
20 After consultation with local
experts we assumed an out migration rate of less than
10%.
We calculated that a cohort of 12000 infants,
randomised in a 1:1 ratio and followed up for two
years, would yield enough cases in each arm to assess
equivalence in the range 2.5% (SD 25%) per annum
witha power(1−β) of0.80 andat a levelofsignificance
(α) of 0.05.
We carried out two interim analyses, 14 and
29 months after the first enrolment when 2674
(22.9%) and 7685 (65.8%) of the total 11680 infants,
respectively, had been enrolled. On each of these
occasionstheresultswerepresentedtoanindependent
international data safety monitoring committee of
seven members, who considered whether the study
should continue, on the basis of prespecified stopping
rules. No rules were applied.
Randomisation, sequence generation, allocation
concealment, implementation, and masking
The study statistician generated the randomisation
sequence in Microsoft Excel. Infants were allocated to
route of BCG vaccine according to the week of birth.
The sequence was balanced in eight week blocks (four
intradermal, four percutaneous). Allocation conceal-
mentandmaskingdidnottakeplace.Participantswere
enrolled by midwives and study counsellors based at
maternity units who were aware of the week’s
allocation.
Statistical analysis
The primary end point was the cumulative two year
incidence of tuberculosis. The numerator for the
calculation was all infants meeting the criteria for
tuberculosis; the denominator was all randomised
infants. Each infant was counted once only and in the
caseofmultiplereferralsforevaluationfortuberculosis
we selected the most severe diagnosis as the outcome.
We calculated exact binomial confidence intervals for
the cumulative incidence rates. To account for two
partially unblinded interim analyses, which used
0.0005 and 0.014% significance levels, respectively,
we used a 4.5% significance level in the final analysis,
Failed to meet inclusion criteria (n=1658)
Received* percutaneous
BCG (n=5775)
Received* intradermal
BCG (n=5905)
Analysed (n=5775) Analysed (n=5905)
Assessed for eligibility (n=13 338)
Enrolment
Randomised by week of birth (n=11 680)
Lost to follow-up (n<584)†, on basis of out
migration surveys (no active follow-up)‡
Discontinued intervention (n=0, one off intervention)
Fig 2 | Participant flow. *Some infants received vaccine
through the alternative route to that allocated for operational
reasons—for example, born shortly before midnight but
vaccinated next morning, after allocation route changed. Sixty
three (0.54%) infants received BCG by non-allocated route; 29
(0.50%) in intradermal group, 34 (0.58%) in percutaneous
group. †10%random sample surveyed and less than 5% could
not be traced. ‡Differential loss to follow-up by group cannot
be calculated as out migration surveys did not collect this
information
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21 Equiva-
lence was shown if the 95.5% confidence intervals for
the incidence rates in the percutaneous group fell
within 25% of those for the intradermal group. We
further compared the cumulative incidence rates for
thegroupsusingriskratiosandcorrespondingFisher’s
exact confidence interval.
We compared the groups for baseline personal and
clinical characteristics using two way analysis of
variance, with vaccine group and study centre as
factors for continuous variables, and the Cochran
Mantel-Haenszel test, controlling for study centre, for
categorical variables. We used cumulative incidence
proportion and exact 95% binomial confidence inter-
valtosummarisethenumberofinfantswithatleastone
serious adverse event, the number of grade 3 and 4
vaccine related adverse events, and the number of
deaths and compared these using risk ratios with
corresponding 95% confidence intervals.
RESULTS
Overall, 13338 pregnant women or those who had
recently delivered were approached to enrol their
infants in the trial (fig 2). In total, 11680 infants were
randomised and vaccinated. Reasons for exclusion
included antenatal and perinatal complications—for
example,stillbirth,prematurity,orintrauterinegrowth
retardation and perinatal infection—as well as women
who had agreed to the trial but declined after
enrolment. Overall, 5905 infants received intradermal
BCG and 5775 percutaneous BCG. During the three
months after birth 4851 infants were followed up for
adverseeventsafterimmunisationandallofthesewere
seen at least once, some more than once. All 11680
infants vaccinated were passively followed up for
tuberculosis, morbidity, and mortality and were thus
included in the primary intention to treat analyses.
Protocol violations
Twohundredandthirtyviolationsoftheprotocolwere
recorded. Eight related to consent, 142 to the infant
being vaccinated more than 24 hours after birth, 63 to
infants assigned to one route but vaccinated by the
alternativeroute,sixtoinfantsvaccinatedafterthetrial
hadfinished,and25tootheraspectsofthevaccination
process.Theseinfantswereincludedintheintentionto
treat analysis. Protocol violations were reported to the
data safety monitoring committee and relevant
research ethics committees. When the violation had
clinical implications, the infant was followed up
appropriately and referred for further assessment if
necessary.
Recruitment and baseline data
The recruitment period spanned three years and four
months, from 26 March 2001 to 31 July 2004. The
follow-up period lasted until 31 July 2006 or until the
infantreached2yearsofage,whicheveroccurredfirst.
Table 1 shows the baseline personal and clinical
characteristics of the infants by vaccination group.
Numbers analysed
All 11680 vaccinated infants were analysed—5775 in
the percutaneous group and 5905 in the intradermal
group. These infants contributed person time to the
denominatorsofthecalculatedrates.Losstofollow-up
was assumed to be evenly split between both routes. It
was not adjusted for in the calculation of incidence
rates.
All infants were analysed in the group to which they
has been randomised, regardless of vaccine received.
Because enrolment into the trial was defined by the
infant being vaccinated and because the intervention
was one off and irreversible, it was not expected that a
per protocol analysis would differ in any significant
way from the primary, intention to treat analysis. No
significant difference was found. For example, the
difference between the intradermal and percutaneous
groupsinthetwoyearcumulativeincidenceofdefinite,
probable,andpossibletuberculosisintheperprotocol
analysiswas0.39%(95.5%confidenceinterval−1.30%
to 0.53%) compared with 0.36% (−1.27% to 0.54%) in
the intention to treat analysis.
Outcomes and estimation
The primary outcome of the trial was documented M
tuberculosis infection or radiological and clinical evi-
dence of tuberculous disease, expressed as the cumu-
lative incidence of definite, probable, or possible
tuberculosis over the two years of follow-up.
Primary outcome
Equivalence was found between the routes using an
endpointofdefinite,probable,orpossibletuberculosis
(table 2 and fig 3).This is because the upper and lower
bounds of the 95.5% confidence intervals around the
point estimate of the rate in the comparator group
(percutaneous) lay wholly within the interval bounded
by the point estimate of the rate in the reference group
(intradermal) plus or minus 25% (4.58% to 7.64%).
22
Analysis of definite and probable cases only and
definite cases alone just failed to show equivalence: in
Table 1 |Comparison of baseline personal and clinical characteristics of infants allocated to
receive BCG vaccination by the intradermal route or percutaneous route. Values are numbers
(percentages) unless stated otherwise
Factor Intradermal BCG (n=5905) Percutaneous BCG (n=5775)
Person years of exposure* 14 576.9 14 376.7
Boys 3026 (51.2) 2917 (50.5)
Mean (SD) gestational age at birth
(weeks)
38.57 (2.23) 38.54 (2.24)
Preterm births (<37 weeks) 1038 (17.6) 981 (17.0)
Caesarean sections 645 (10.9) 635 (11.0)
Multiple births 48 (0.8) 70 (1.2)
Mean (SD) birth weight (g) 2930 (530) 2930 (530)
Low birth weight (≤2500 g) 1234 (20.9) 1185 (20.5)
Mean(SD)maternalageatinfant’sbi rt h
(years)
25.70 (6.45) 25.65 (6.38)
*Time from vaccination date to date of diagnosis of most severe tuberculosis.
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interval around the point estimate of the cumulative
incidence in the percutaneous group lay marginally
abovethe25%bandandinthesecondcasemarginally
below the band.
Few cases of disseminated tuberculosis were
detected and there were no statistically significant
differences by route of vaccination. Three cases of
tuberculous meningitis occurred in the intradermal
group and one in the percutaneous group (risk
difference 0.03%, 95% confidence interval −0.03% to
0.10%).Nocasesofmiliarytuberculosisoccurredinthe
intradermal group but one occurred in the percuta-
neousgroup(riskdifference−0.02%,−0.05%to0.02%).
One case of abdominal tuberculosis and one case of
spinal tuberculosis occurred in the percutaneous
group. No statistical comparisons were made because
of the small number of infants.
Only those infants who were suspected of having
tuberculosis and who were admitted to the ward for
investigations were tested for HIV. Thirty one of 1576
(1.97%) tested positive (enzyme linked immunosor-
bent assay, confirmed by polymerase chain reaction if
the infant was less than 18 months old); 9.7% of these
were diagnosed as having definite tuberculosis, 35.5%
as having probable tuberculosis, and 16.1% as having
possible tuberculosis.
Secondary outcomes: adverse events
Overall, 2180 infants were admitted to hospital. The
cumulative incidence was 18.7% (1091 (18.5%) in
intradermal group, 1089 (18.9%) in percutaneous
group): risk ratio 0.98 (95% confidence interval 0.91
to 1.06).
Twenty one grade3 and onegrade4 vaccinerelated
adverse reactions occurred. Of these, 16 were keloids
(10 in intradermal group, six in percutaneous group,
risk ratio 1.63, 0.59 to 4.48) and five were cases of
suppurativeaxillarylymphadenitis(twoinintradermal
group, three in percutaneous group, risk ratio 0.65,
0.11 to 3.90), two of which progressed to breakdown
withtheformationofadrainingsinus.Noneofthefive
infants was infected with HIV. The lesions resolved
with conservative management without the use of
systemic or local antituberculosis drugs.
One case of disseminated BCG disease was diag-
nosed in an infant who had received percutaneous
BCG. The diagnosis was made after culture of a
mycobacterium from gastric washings, which was
subtyped as M bovis BCG substrain Tokyo 172. The
infantwasnotinfectedwithHIV,buthadevidenceofa
primaryimmunedeficiency,whichwasinvestigatedat
a specialist clinic at a tertiary academic hospital.
Onehundredandeightysixinfantsdied(102(1.73%)
in intradermal group, 84 (1.45%) in percutaneous
group, risk ratio 1.19, 0.89 to 1.58). The cumulative
incidence was 1.59%. None of these deaths was
considered to be related to the intervention. Addition-
ally, no deaths were considered to be caused by
tuberculosis, although four were “associated with” the
disease, two in the intradermal group and two in the
percutaneous group. The causes of death are covered
elsewhere.
23
DISCUSSION
In a randomised trial we found equivalence in the
cumulative incidence of definite, probable, and possi-
ble tuberculosis in infants before age 2 years who
received either intradermal BCG or percutaneous
BCG at birth.
The diagnosis of tuberculosis in infants is difficult.
The most robust definition of tuberculosis in this age
group is definite or probable. This was not used as the
primary outcome in this trial for several reasons.
Tuberculosisinyoungchildrenincountrieswithahigh
burden of tuberculosis is generally not diagnosed on
the basisof culturesowing tounavailability. Therefore
the incidence of culture positive tuberculosis in a
community trial such as this was difficult to predict. It
was always intended that several case definitions and
endpointswouldbeexploredintheanalysis.Norecent
and few older trials of tuberculosis vaccines in young
children and infants were available on which to model
this trial. It is encouraging that there is some
consistency in the primary result regardless of the
case definition used. Part of the reason for doing the
trial was to develop a robust case definition and end
point for use in future phase III trials of new
tuberculosis vaccines.
For a variety of reasons the intradermal route for
administering BCG vaccine is currently the most
widely used worldwide and is the only method
advocated by WHO.
5 Although evidence is scant, a
2004 review of studies comparing the intradermal
route with the percutaneous route found that percuta-
neous BCG is less efficient in stimulating interferon-γ
production by Th1 lymphocytes and suggested that
intradermal BCG should be recommended.
5 This
route is, however, technically more challenging and
as such requires more training of operators and more
intensive quality control of the immunisation pro-
gramme.Inmanyareasoftheworld,includingseveral
countries with a high burden of tuberculosis, these
extra resources are not available, with the result that
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cumulative incidence of tuberculosis over two years by end
point
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techniques and after little or suboptimal training. Our
results support allowing national or regional pro-
grammes for tuberculosis control to decide which
route to use, basing their decision on other considera-
tions such as logistics, training, economic factors, and
product availability.
The rates of tuberculosis were high, given the
documented quality controlled vaccination of the
infants. Regardless of which route worked better,
neither worked particularly well in preventing pul-
monary disease, with over 6% of properly vaccinated
infants developing definite, probable, or possible
tuberculosis over the two years after birth. Even if
possible cases were discounted, because of less
confidence in the diagnosis, the rate is over 3%. A
counter argument is that we have no way of knowing
what the rate would be in the absence of BCG
vaccination since placebo controlled trials are not
possible, and thus we have no way of determining
overall vaccine efficacy.
Wefoundfewcasesofdisseminatedextrapulmonary
tuberculosis.Disseminateddiseasemaycompriseover
25% of all cases of tuberculosis in children aged
0-14 years
2425 and tuberculous meningitis in the
Western Cape Province of South Africa has been
reported to occur at rates of 0.03% per year in infants
aged less than 1 year and 0.02% per year in children
aged1-4years.
26Wedetectedfourcasesoftuberculous
meningitis, giving a cumulative incidence over two
years of 0.03% or 0.015% per year, about half of that
expected. Miliary tuberculosis is said to occur in
around 2.7% of children with active tuberculosis.
27
Given our calculated cumulative incidence of all
tuberculosis over two years of 6.31%, we should have
seen a cumulative incidence of miliary tuberculosis of
around 0.17% over two years, or 20 cases. We,
however, saw one case, giving a cumulative incidence
over two years of 0.009%, about 20 times less than
expected.
There are several possible explanations for this.
Firstly, the process of carrying out the trial brought
considerable resources into the study site that had not
been available previously. Some of these resources
were used to trace contacts of adults with tuberculosis,
to intensively evaluate them for tuberculous disease,
and to refer them for prophylaxis or treatment if they
wereinfectedordiseased.Becauseofthis,manyinfants
weredetectedsoonaftertheyhadbeeninfectedwithM
tuberculosis, before they could develop clinical disease.
Allwerereferredforacourseofprophylactictreatment
(three months of daily rifampicin plus isoniazid), and
this would have prevented most of them developing
severe pulmonary or disseminated disease. Tracing
and correctly managing contacts of children with
tuberculosis will remain vital parts of all tuberculosis
control programmes until and even after a more
effective vaccine becomes available.
Secondly, our ability to detect cases of disseminated
disease was perhaps suboptimal and we possibly
missed cases and deaths due to such disease. Health
providers in South Africa are, however, well aware of
the condition and we think it is unlikely. Thirdly, our
cases of pulmonary tuberculosis may not have been
“real cases”—we were identifying infants with sub-
clinical disease but positive culture results, some of
whomwouldpossibly,ifleft,haveselfcured.Allcases,
however, met internationally accepted definitions of
paediatrictuberculosisandallwould,ifseenpurelyina
clinical setting in South Africa, have been placed onto
full chemotherapy (all were referred for this reason).
Fourthly, the “missing” cases of severe and dissemi-
nated disease may have been prevented by a more
rigorous BCG immunisation programme and better
qualitycontrol.Fifthly,oursamplewasbiasedtowards
more healthy newborn infants—those ineligible to
receive routine BCG vaccination within 24 hours of
birthwereexcludedfromparticipation.Thismayatthe
same time have excluded those most likely to develop
disseminated disease. Lastly, our estimates of the
expected numbers of infants with miliary tuberculosis
and tuberculous meningitis may be wrong.
Overall, 186 infants died. A mortality surveillance
system was developed to identify and document the
causes of death as far as possible. Pneumonia, gastro-
enteritis, and septicaemia were among the commonest
causes of mortality, and important underlying causes
included HIV/AIDS, prematurity, low birth weight,
and malnutrition. In this cohort, mortality was largely
due to infectious diseases. For several reasons, how-
ever, many deaths could only be categorised as
“sudden unexplained” or as “ill defined,” illustrating
thedifficultyofdoingaccuratemortalitysurveillancein
field trials in developing countries. This has important
implications for future phase III efficacy trials carried
out for product registration.
Morethanoneinsixinfants(n=2180)wereadmitted
to hospital at least once during the course of the trial,
emphasising the amount of comorbidity in this
community. The number of adverse vaccine reactions
Table 2 |Number of infants with tuberculosis by route of BCG administration, diagnosed within two years of birth in case
verification ward
Classification
Intradermal BCG
(n=5905)
%
(95.5% CI)
Percutaneous BCG
(n=5775)
%
(95.5% CI)
Difference (intradermal
−percutaneous)
Definite tuberculosis 89 1.51 (1.20 to 1.86) 83 1.44 (1.14 to 1.79) 0.09 (−0.37 to 0.54)
Probable tuberculosis 95 1.61 (1.30 to 1.97) 118 2.04 (1.69 to 2.51) −0.42 (−0.93 to 0.08)
Possible tuberculosis 178 3.01 (2.58 to 3.49) 174 3.01 (2.58 to 3.50) −0.03 (−0.68 to 0.61)
Definite,probable,and
possible tuberculosis
362 6.13 (5.52 to 6.79) 375 6.49 (5.86 to 7.18) −0.36 (−1.27 to 0.54)
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axillary lymphadenopathy (0.4%) and one case of
disseminated BCG infection (0.01%).
Technical issues
We were not able to show equivalence in the
cumulative incidence of definite and probable tuber-
culosis or of definite tuberculosis only between the
groups, and in the definite only group the difference
was in the opposite direction, with the rate in the
percutaneous group being marginally lower. We
believe that the explanation for this observation lies
withthesamplesizeofthestudy,whichwaspoweredto
detect a difference using the most sensitive and least
specific end point and that had our numbers been
larger we would have shown equivalence for both the
alternative, more specific end points. The apparent
reversal of directionwas, we feel, a function of chance.
The finding does, however, underline the importance
ofhavingaclearandrobustendpointandbeingableto
define what a “case” of tuberculosis is for the purposes
of a phase III trial of any novel tuberculosis vaccine.
Potential sources of bias and imprecision and study
limitations
Allocation concealment—Mothers of potentially
eligible infants were asked to decide whether to enrol
thembeforebeinginformedoftherouteofvaccination
for the current week. Refusal rates were low and no
greater for one route than the other. Eleven of 11691
women gave consent before delivery but refused to
confirm consent after delivery.
Primaryoutcomeassessment—Itwasnotpossible
to blind field staff assessing outcomes such as
tuberculosis and adverse reactions to the route of
vaccination. Chest radiography and microbiological
testssuchassmearsandcultureswere,however,always
carried out and reviewed in a blinded fashion, and the
final categorisation of cases was done blinded.
Laboratory contamination—A quality control
programme was established during the trial, in which
dummy sterile specimens were regularly submitted to
the microbiology laboratory along with routine speci-
mens.Astheprogrammewasnotinplacefromthestart
and for other reasons, we cannot definitively exclude
cross contamination as a source of some positive
culture results. It is possible that we overestimated the
absolute rates of culture positive tuberculosis in the
cohort.
Review of chest radiographs—Reviewers were
asked to classify x ray films using standard criteria and
withoutaccesstotheclinicaldetailsoftheinfant.When
there was disagreement between reviewers we
accepted a two thirds majority as definitive.
Assessment of exposure to tuberculosis—The
caregivers’ recall ofexposureto contacts asa means of
establishing epidemiological linkage may be inaccu-
rate. The significance of a tuberculin skin test result is
difficult to gauge in a population where malnutrition
and other causes of suppressed cellular immunity are
rife, BCG vaccination is close to universal, and
exposure to non-tuberculous mycobacteria common.
Clinical diagnosis of tuberculosis—The clinical
diagnosis of paediatric tuberculosis is subjective and
consequently imprecise given that the symptoms and
signs of tuberculosis in children are non-specific.
External validity of study findings—We enrolled
about two thirds of the region’s birth cohort. Those
infants who were not enrolled might have come from
families that were poorer and more likely to have
tuberculosis. We included only infants who were
eligible for routine BCG vaccination at birth. Our
results may therefore be less generalisable, specifically
to groups at higher risk of tuberculosis than our study
cohort—those with an annual risk of infection of more
than 4% and those that include large proportions of
preterm, low birthweight infants.
Strain of vaccine—Many strains of BCG exist. We
compared two routes for giving a single substrain of
BCG (Tokyo 172). It is possible that some strains of
BCG are more efficacious than others in preventing
tuberculosis.
14152829 Our finding of an equivalent
incidence of tuberculosis between routes may not be
generalisable to other substrains of BCG.
Childrendiagnosedoutsidethecaseverification
ward—One hundred and sixteen children were
diagnosed as having tuberculosis outside the case
verification ward: 63 of these were in the intradermal
groupand53inthepercutaneousgroup.Childrenwith
tuberculosis who were not detected by community
surveillanceandwhowere investigatedand diagnosed
as having tuberculosis during a routine hospital
admissionwerelikelytohavemoreadvancedtubercu-
losis, including meningitis and miliary disease, but
were likely to have more missing diagnostic data.
Therefore, for the purpose of the primary analysis, we
included only those children diagnosed as having
tuberculosis on the ward. The ward admitted infants
throughout the trial, but we included only children
investigated for tuberculosis before their second birth-
day in the primary analysis. Retrospective sensitivity
analyses were done that included all infants with a
diagnosis of tuberculosis while on the ward and in the
communityandallinfantsinvestigatedfortuberculosis
before and after age 2 years. These analyses did not
significantly change the relative efficacy estimates.
WHAT IS ALREADY KNOWN ON THE TOPIC
VaccinationofnewborninfantswithBCGprovidesvariableandincompleteprotectionagainst
tuberculosis
WHO and most countries advocate the intradermal route for administering BCG vaccine
No study to date has provided clear evidence that one route of vaccination is safer, more
immunogenic, or more efficacious than the other
WHAT THIS STUDY ADDS
The intradermal route for administering BCG vaccine to infants and young children was as
efficacious as the percutaneous route for preventing tuberculosis
RESEARCH
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believe that none should have significantly influenced
the derived relative efficacy estimates.
The trial was not designed to provide an accurate
estimation of the relative reactogenicity of the two
routes. This was because surveillance was largely
passive and infants who develop “minor” adverse
events after immunisation do not generally present to
healthcarefacilitiesinSouthAfrica.Onlythoseinfants
who experienced major reactions, such as suppurative
lymphadentitis, could be identified.
Conclusion
In conclusion, the intradermal and percutaneous
routes for BCG vaccination were equivalent for
efficacy and safety. In addition to this some important
issues will need to be overcome before phase III
efficacy trials of new tuberculosis vaccines in young
children can be carried out. This study allowed us to
start putting together the necessary infrastructure for
such trials, at least at one field site. Our results have
important implications for tuberculosis control pro-
grammes and vaccination programmes that still
advocate the use of intradermal BCG.
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